21
July
2015
|
00:00
Europe/Amsterdam

Heart Failure Patients Now Have Expanded Therapy Options and Unique Pacing Features with New BIOTRONIK CRT-D Device

First US Patients Implanted with Itrevia HF-T QP, Incorporating Latest Defibrillator Technology, Closed Loop Stimulation and Compatibility with a Quadripolar Lead, to Help Patients with Heart Failure Conditions

LAKE OSWEGO, Oregon, July 21, 2015 – BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today that the first patients have been successfully implanted with Itrevia HF-T QP cardiac resynchronization defibrillator (CRT-D) devices. Itrevia HF-T QP includes the unique Closed Loop Stimulation (CLS) algorithm. Only CLS is capable of appropriately adapting heart rate in response to physiological demands independent of body movements or respiratory rate.

Itrevia HF-T QP was recently approved by the Food and Drug Administration (FDA) for use with IS4 compatible left ventricular (LV) leads. The CRT-D device has a quadripolar header, which gives more LV pacing options to optimize the CRT therapy.

“This device meets standards of other devices in the market and then adds CLS,” said Dr. Alexander Mazur, MD, Clinical Associate Professor from the University of Iowa in Iowa City. “My patients with heart failure have greater risk of falling due to the incidence of orthostatic hypotension and it is beneficial to have the option of using CLS to treat them.”

Orthostatic hypotension occurs in 30-50 percent of elderly patients with disease or medication risk factors and is associated with falls, syncope and hospitalization. The CLEAR study shows a 75 percent reduction in the prevalence of orthostatic hypotension with the CLS algorithm compared to an accelerometer, which most other CRT-D devices use.1 Accelerometers are mechanisms that sense physical activity and require patients to be in motion before increasing their heart rate. Yet, patients need appropriate rate response regardless of whether they are actively moving or completely still. CLS mimics the human nervous system more closely, responding to the patient’s metabolic changes and acute mental stress and adjusting the heart rate without relying on motion, as an accelerometer does. CLS, available in BIOTRONIK pacemakers since 2003, has been clinically proven to be more responsive in activities of daily living than accelerometers.1

Similar to BIOTRONIK’s Itrevia ICD and CRT-D series, released earlier this year, Itrevia HF-T QP includes additional advanced therapies: morphology discrimination, atrial capture control, improved ATP optimization and more LV pacing vectors. Combined, they deliver more effective therapeutic options while reducing unnecessary shocks. All devices include BIOTRONIK Home Monitoring®, the first remote monitoring system and the only system with automatic daily transmission, which has been shown to reduce all-cause mortality by more than 50 percent in heart failure patients.2

“The FDA has approved CLS as the only system to respond to acute mental stress and now this unique technology is available for more patients who can benefit from the expanded programming options of a quadripolar device,” said Marlou Janssen, President, BIOTRONIK, Inc. “CLS and BIOTRONIK Home Monitoring are core technologies in our BIOTRONIK pacemakers and ICDs because we know, and have clinical evidence, that these technologies can improve the quality of patients’ lives.”

  1. Abi-Samra F.M. et al. Europace. 2013, 15(6):849-56.
  2. Hindricks G. et al. The Lancet. 2014, 384(9943).

About BIOTRONIK:

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.